PASSAGE BIO INC
PASGNASDAQTrading Snapshot
- Day Range
- $4.44 – $4.53
- 52-Week Range
- $3.29 – $20.00
- Volume
- $1.90B
- Avg Volume
- $2.53B
- Shares Outstanding
- 3.2M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $522,868
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-11.84
- Dividend Yield
- —
Why Investors Own PASG
- ✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PASSAGE BIO INC
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.